Low Serum Allopregnanolone Is Associated with Symptoms of Depression in Late Pregnancy

Charlotte Hellgren a  Helena Åkerud a  Alkistis Skalkidou a  Torbjörn Bäckström b  Inger Sundström-Poromaa a

a Department of Women’s and Children’s Health, Uppsala University, Uppsala, and b Umeå Neurosteroid Research Center, Department of Clinical Science, Obstetrics and Gynecology, Umeå University, Umeå, Sweden

Key Words
Allopregnanolone · Anxiety · Depression · Montgomery-Åsberg Depression Rating Scale · Pregnancy · Spielberger State-Trait Anxiety Inventory

Abstract
Background: Allopregnanolone (3α-hydroxy-5α-pregnan-20-one) is a neurosteroid which has an inhibitory function through interaction with the GABA A receptor. This progesterone metabolite has strong sedative and anxiolytic properties, and low endogenous levels have been associated with depressed mood. This study aimed to investigate whether the very high serum allopregnanolone levels in late pregnancy covary with concurrent self-rated symptoms of depression and anxiety.

Methods: Ninety-six women in pregnancy weeks 37–40 rated symptoms of depression and anxiety with the Montgomery-Åsberg Depression Rating Scale (MADRS-S) and Spielberger State-Trait Anxiety Inventory. Their serum allopregnanolone was analyzed by Celite chromatography and radioimmunoassay.

Results: Ten women had elevated depression scores (MADRS-S ≥ 13), and this group had significantly lower allopregnanolone levels compared to women with MADRS-S scores in the normal range (39.0 ± 17.9 vs. 54.6 ± 18.7 nmol/l, p = 0.014). A significant negative correlation was found between self-rated depression scores and allopregnanolone concentrations (Pearson’s correlation coefficient = −0.220, p = 0.031). The linear association between self-rated depression scores and allopregnanolone serum concentrations remained significant when adjusted for gestational length, progesterone levels, and parity. Self-rated anxiety, however, was not associated with allopregnanolone serum concentrations during pregnancy.

Conclusion: High allopregnanolone serum concentrations may protect against depressed mood during pregnancy.

Introduction
Allopregnanolone (3α-hydroxy-5α-pregnan-20-one) is a steroid which allosterically enhances GABAergic signaling at GABA A receptors [1]. Allopregnanolone is synthesized in the brain, but the main sources of serum allopregnanolone in nonpregnant women are the corpus luteum and the adrenal cortex [2, 3]. During the men-
strual cycle, serum allopregnanolone concentrations vary between around 0.5 nmol/l in the follicular phase, and 4–5 nmol/l in the mid-luteal phase [2]. During pregnancy, fetoplacental synthesis causes the maternal serum concentrations of allopregnanolone to continuously rise to eventually reach more than 10 times the maximum menstrual cycle levels [4–6]. After delivery, the allopregnanolone level rapidly drops to 2 nmol/l within a few days, but slightly elevated levels (approximately 1 nmol/l) are seen several weeks following parturition [7, 8]. When intravenously administered to nonpregnant women, pregnancy-like allopregnanolone serum concentrations are sedative [9], and impair immediate recall [10], symptoms which do not affect late pregnant women in general [11]. These observations suggest that a tolerance to allopregnanolone develops during pregnancy.

Low levels of allopregnanolone have been implicated in mood disorder pathophysiology, for example, successful treatment with selective serotonin reuptake inhibitors increases plasma and cerebrospinal fluid allopregnanolone in patients with major depression [12, 13]. However, increased serum allopregnanolone has also been observed after unsuccessful treatment with antidepressants [14], and no increase has been shown after successful electroconvulsive treatment [15]. Furthermore, altered neurosteroid metabolism has been observed in women with remitted depression compared to women with no history of depression [16]. Lower serum allopregnanolone in depressed compared to healthy menopausal women has also been reported [17]. Thus far, only one study has investigated the relationship between pregnancy allopregnanolone levels and depression, and found no difference in allopregnanolone levels between pregnant women with and without depression [8]. However, lower allopregnanolone levels after delivery have been found in women who develop postpartum blues [7], and for this reason, postpartum blues has been suggested to be an effect of withdrawal from allopregnanolone [18]. Hypothetically, women with higher allopregnanolone concentrations during pregnancy could be subjected to a more marked drop after delivery, and thereby be more susceptible to depressive symptoms postpartum, while they could be more protected from depression during pregnancy.

When administered acutely to female rats, allopregnanolone is known to be anxiolytic [19], whereas prolonged administration or withdrawal from allopregnanolone may precipitate increased anxiety [18]. Allopregnanolone is partly responsible for the decreased hypothalamic-pituitary-adrenal (HPA) response to stress seen in rats during pregnancy [20], and possibly also for the decreased anxiety behavior of pregnant rats [21]. Although the endocrine stress response is decreased also in human pregnancy, longitudinal data suggests that anxiety levels in healthy women are unchanged by pregnancy [22]. In addition, endogenous levels of allopregnanolone do not seem to be altered in anxiety disorders [23–26], other than panic disorder [27, 28].

The primary aim of this study was to assess self-rated symptoms of depression and anxiety in relation to serum levels of allopregnanolone in pregnant women. We hypothesized that higher levels of allopregnanolone during late pregnancy would be protective against concurrent symptoms of depressed mood and anxiety.

Methods

Subjects

Ninety-eight women in pregnancy weeks 37–40 were recruited through public maternity health care units in Uppsala County and through local newspaper advertisements. Women above 18 years of age with an uncomplicated singleton pregnancy were eligible for inclusion. Two women were excluded because of ongoing treatment with selective serotonin reuptake inhibitors, thus 96 women were included in the analyses.

The study procedures were in accordance with ethical standards for human experimentation and the study was approved by the Regional Ethical Review Board in Uppsala.

Procedure

The participants were scheduled to visit the Department of Women’s and Children’s Health, Uppsala University, between 08.00 h and 18.00 h, approximately 2 weeks before their estimated date of delivery. Upon arrival, they provided written informed consent and had a blood sample taken. All women were asked about obstetric history, medication during the preceding 3 months, and tobacco and alcohol use. Ongoing depressive disorders and ongoing primary anxiety disorders were assessed with the Mini International Neuropsychiatric Interview, a structured interview based on DSM-IV criteria [29].

Subjects also filled out the Montgomery-Åsberg Depression Rating Scale (self-rated version, MADRS-S) [30] and the Spielberger State-Trait Anxiety Inventory (State and Trait versions, STAI-S and STAI-T, respectively) [31]. Although the MADRS-S is primarily designed to detect change, a score of 13 or more is commonly used in Swedish primary care to screen for ongoing depression, and was considered as an elevated depression score in this study. In the STAI-S and -T, a cut-off score of 40 gives around 80% sensitivity and specificity for anxiety disorders in a pregnant population [32].

First-trimester weight, date of delivery, and information on obstetric complications were extracted from hospital records.

All participants received the Swedish version of the Edinburgh Postnatal Depression Scale (EPDS) [33, 34] form to fill in and return by mail at six weeks after the delivery. As suggested by the Swedish EPDS validation [34], a score of 12 or more was considered screen-positive.
Serum Steroid Concentration Analyses
A blood sample was collected by antecubital vein puncture and centrifuged at 1,500 g for 10 min and stored at –20 °C within an hour after sampling. The estradiol and progesterone analyses were carried out by competitive immunometric electrochemiluminescence detection at the Department of Clinical Chemistry, Uppsala University Hospital. The samples were run on a Roche Cobas e601 with Cobas Elyse estradiol and progesterone reagent kits, respectively (Roche Diagnostics, Bromma, Sweden). For progesterone the measurement interval was 0.1–191 nM and for estradiol 18.4–15,781 pmol/l. Progesterone intra-assay coefficient of variation was 2.2% at 2.39 nmol/l and 2.8% at 31.56 nmol/l. The total coefficient of variation was 4.8% at 2.52 nmol/l and 2.0% at 112 nmol/l. Estradiol intra-assay coefficient of variation was 6.8% at 85.5 pmol/l and 2.8% at 1,640 pmol/l. The total coefficient of variation was 4.7% at 120 pmol/l and 2.6% at 12,935 pmol/l.

Allopregnanolone serum concentrations were determined by Umeå Neurosteroid Research Center, as previously described [9]. Briefly, serum allopregnanolone was measured using radioimmunoassay after extraction with diethyl ether and purification by Celite chromatography because of the cross-reactivity of the antibody used was raised against 3α-hydroxy-20-oxo-5α-pregnan-11-yl carboxymethyl ether coupled with bovine serum albumin as antigen (AgriSera AB, Umeå, Sweden). All samples were counted in a RackBeta (Wallace, Finland) scintillation counter.

Statistical Analyses
With a standard deviation (SD) of 14 nM [5] we had a power of 0.83 to detect a mean difference of 15 nM between the women with depression scores of 13 or more and women with depression scores in the normal range. Allopregnanolone and estradiol concentrations, trait anxiety scores, and days to delivery were found to be normally distributed (Shapiro-Wilk, W > 0.95). However, the depression scores (MADRS-S and EPDS), progesterone concentrations, state anxiety scores, and weight were not considered normally distributed (Shapiro-Wilk, W < 0.95), but Pearson’s correlations were calculated since the unstandardized residuals of each presented univariate linear correlation were found to follow normal distribution. However, potential differences in hormonal and demographic variables between women with MADRS-S scores ≥13 and <13 were assessed with the Mann-Whitney U test, or Fisher’s exact test.

The association between allopregnanolone and depression scores, adjusted for potential confounders, was tested with linear regression.

SPSS Statistics 20 (IBM) was used in all statistical analyses; p values <0.05 were considered statistically significant and data is presented as mean ± SD unless stated otherwise.

Results
Demographic Factors and Obstetric Outcome
The mean age of the women was 30.7 ± 4.5 years and 55 (57.3%) were nulliparous (pregnant with their first child). The assessments were made in gestational week 38.2 ± 0.6 and the median number of days until parturition was 13.5 days (range 1–32 days). All but 1 woman were married or cohabiting. No women reported use of alcohol during pregnancy, but 1 woman reported tobacco use. Eight women (8.3%) were delivered by Caesarean section and the remaining women had a vaginal delivery. None of the women experienced any severe delivery complications.

Depression and Anxiety during Pregnancy
Ten women (10.4%) had MADRS-S scores ≥13, indicating ongoing depressive symptoms. According to the Mini International Neuropsychiatric Interview, 2 women (2.1%) had an ongoing major depressive episode, 1 woman (1.0%) had obsessive compulsive disorder, and 1 woman (1.0%) was found to suffer from recurrent panic attacks but without fulfilling the criteria for panic disorder; these 4 women also had MADRS-S scores ≥13. Additional study population characteristics including mean MADRS-S and STAI and steroid hormone concentrations are found in table 1.

Steroid Concentrations in Relation to Depression and Anxiety Scores during Pregnancy
Clinical characteristics and hormonal serum concentrations in women who had elevated or normal range depression scores are given in table 2. Women with elevated depression scores had significantly lower allopregnanolone serum concentrations than women with depression scores in the normal range [medians (interquartile range) 36.9 (23.8–50.1) vs. 51.8 (40.7–67.3) nM/l, p=0.014, table 2]. The 4 women who had an anxiety or depressive disorder according to Mini International Neuropsychiatric Interview had a mean allopregnanolone plasma concentration of 27.2 ± 10.3 nM/l.

Allopregnanolone serum concentrations were in statistically significant negative correlation with self-report-
ed depression scores (Pearson’s correlation coefficient = –0.220, p = 0.031; fig. 1).

Neither progesterone nor estradiol concentrations were associated with pregnancy depression scores (both p > 0.20). State and trait anxiety ratings were not correlated with allopregnanolone, estradiol, or progesterone concentrations (all p > 0.20).

Allopregnanolone was also associated with the number of days left to delivery, and serum progesterone (table 3). There was no effect of time of blood sampling on the allopregnanolone concentration (a.m. vs. p.m. samples, p = 0.213).

A greater proportion of women with elevated depression scores had previously given birth, although this difference was not significant (p = 0.092, Fisher’s exact test). No other significant differences in age, first-trimester weight, progesterone, or estradiol levels were found between women with or without elevated depression scores.

The correlation between allopregnanolone and depression score remained after adjustment for days left to delivery, serum progesterone, and nulliparity (table 4).

**Postpartum Depression Scores**

Ninety women (93.8%) sent in their EPDS forms at 6.9 ± 1.8 weeks postpartum. Seven of them (7.8%) had a score of ≥12, one of whom had elevated depression scores also during late pregnancy. However, 4 of the women who had pregnancy MADRS-S scores ≥13 did not return their postpartum EPDS forms. There was no association between postpartum depression scores and allopreg-
nanopregnanolone concentrations during pregnancy (Pearson correlation 0.047, p = 0.658), and thus we did not proceed with regression analysis.

**Discussion**

We observed a negative association between late pregnancy serum allopregnanolone and self-rated depression scores. This association was driven by the women who had elevated depression scores, who displayed significantly lower allopregnanolone serum concentrations in comparison with women with scores in the normal range.

In disagreement with our results, one previous study examining clinically depressed and euthymic pregnant women found no difference in allopregnanolone levels [8]. One explanation for the discrepant findings could be that the group sizes of Pearson Murphy et al. [8] were too small to detect the relatively modest effect of allopregnanolone suggested by our results. In addition, Pearson Murphy et al. [8] studied a population of women with first onset of clinical depression during pregnancy; our subjects represent a relatively healthy pregnant population with varying degrees of depressed mood, in most cases outside the range of clinical disease. However, the allopregnanolone precursor 5α-dihydroprogesterone was elevated in the depressed women in the study by Pearson Murphy et al. [8], indicating a related neurosteroid imbalance. While the conflicting results underline the lack of direct clinical value of allopregnanolone during pregnancy, together they provide evidence for the importance of a general neurosteroid balance. Pregnancy and the postpartum period entail large neuroendocrine changes, and often increased stress. It is possible that the elevation of neuroactive progesterone metabolites, with their inhibitory potential, is one of the factors which ensure that most women maintain good mental health throughout these challenges [7, 8], but that it is of less relevance for the development of clinical depression during pregnancy [8]. However, the lack of 5α-dihydroprogesterone analysis in the current study is a limitation to further elucidation of this idea.

Decreased allopregnanolone levels are found in major unipolar depression in humans [12, 13] and are related to anxiety- and depression-like behaviors in rodent models of mood disorders [35–37]. Low concentrations of allopregnanolone also correspond with anxiety levels and altered GABA<sub>A</sub> receptor function across the rodent estrous cycle [38, 39]. However, the lowest allopregnanolone level within our study population was more than 7 times higher than typical maximum menstrual cycle levels [40], therefore no participant can be said to have had a low allopregnanolone serum concentration. It is also obvious that depression and anxiety are at least as common during pregnancy as during other time points in a woman’s fertile life [41], despite the anxiolytic and sedative levels of allopregnanolone. Given the possibility that a tolerance develops during several months of continuous increase [42], it is reasonable that only women with very high levels, or a steeper increase, would benefit from the protective effects of allopregnanolone during pregnancy. Insensitivity to other substances acting on the GABA<sub>A</sub> receptor, as well as tolerance to the anticonvulsive, learning-impairing, and anesthetic effects of allopregnanolone exposure have been demonstrated in rodent models [42]. The GABA<sub>A</sub> receptor sensitivity to allopregnanolone may depend on receptor subunit composition, where the relative contributions of subunits a4 and δ have received most attention [43, 44]. It is thus possible that altered subunit composition induces tolerance development during pregnancy, although it remains to be proven in humans.

Evidently, serum concentration is a very blunt measure when studying the effect of allopregnanolone on mood, which is most likely determined by local changes in neurosteroid synthesis and GABA<sub>A</sub> receptor subunit composition within the brain [43]. However, the association we observed suggests that the massive increase in peripheral fetoplacental allopregnanolone synthesis has the potential to affect the central nervous system and protect some women from negative mood symptoms in late pregnancy. Allopregnanolone readily crosses the blood-brain barrier, therefore the serum levels of the steroid are correlated with brain tissue levels [45]. In addition, allopregnanolone is accumulated in adipose tissue and in certain brain areas in rats [44].

In nonpregnant women, allopregnanolone release is coupled to HPA-axis activity [46]. Allopregnanolone decreases the HPA response in pregnant rodents [20] and

**Table 4.** Linear regression of explanatory variables for MADRS-S score during pregnancy

| Variables in model | Linear model β (95%) | p value |
|--------------------|-----------------------|---------|
| Unadjusted         |                       |         |
| Serum allopregnanolone | -0.050 (-0.095 to -0.005) | 0.031   |
| Adjusted           |                       |         |
| Serum allopregnanolone | -0.056 (-0.111 to -0.001) | 0.048   |
| Days to delivery   | -0.022 (-0.140 to -0.095) | 0.707   |
| Serum progesterone | 0.001 (-0.004 to 0.005) | 0.796   |
| Nulliparity        | -0.177 (-1.594 to 1.949) | 0.843   |
in addition to the direct GABA-enhancing effect, allo-
pregnanolone administration affects the transcription of
genes involved in HPA-axis regulation in rats [47]. Thus,
there is a possibility that the association seen in our study
is mediated by HPA-axis regulation effects on mood [48].

Based on rodent studies [19, 21], we had expected that
high serum allopregnanolone would be a protective fac-
tor also against symptoms of anxiety. We found no such
effect, perhaps because of our relatively nonanxious study
population. It must also be mentioned that we measured
state anxiety (referring to the momentary anxiety at the
visit), and trait anxiety (referring to anxiety-prone per-
sonality), with the STAI inventory, which may have tar-
geted negative affect more than symptoms of anxiety [49].

In addition, no association of allopregnanolone to
postpartum depressive symptoms was found. Nappi et al.
[7] have indicated a role for allopregnanolone withdraw-
al in the development of postpartum blues by reporting a
negative correlation between clinician-rated depression
scores and serum allopregnanolone in women 3 days af-
after delivery. While their correlation is in agreement with
our results during pregnancy, we could not show that a
larger withdrawal, as approximated by higher pregnancy
allopregnanolone, would increase depression scores also
at 6–8 weeks postpartum. This can be due to the positive
attrition in our postpartum depression score measure-
ment, or to the fact that different rating scales were used
on the two occasions, but it is also likely that allopre-
gnanolone withdrawal has a larger influence during the
first days following delivery than several weeks into the
postpartum period. Clearly, this remains speculative due
to our cross-sectional allopregnanolone analysis and fur-
ther longitudinal studies are needed.

An important limitation to our study is the small num-
ber of women with symptoms of depression, which opens
up for the possibility of a type I error. A 10% point preva-
ience of self-rated symptom scores indicating depression in
late pregnancy is comparable with population-based stud-
ies [50, 51], but future studies with larger numbers of wom-
en suffering from depressed mood are needed to prove the
validity of the association with serum allopregnanolone.

In conclusion, the observed association between allo-
pregnanolone and self-rated depression score indicates a
role for allopregnanolone in mood regulation also during
pregnancy. Although our findings may not be generalized
to pregnant women suffering from major depression, the
results are relevant for generally healthy pregnant women
who experience mood symptoms during pregnancy.

Acknowledgments

The authors would like to sincerely thank the women who par-
ticipated in this study. The authors would also like to express their
gratitude to Lena Moby for valuable help during the study. In ad-
novation, Lisa Wernroth, and Liisa Byberg from Uppsala Clinical Re-
search Center are acknowledged for helpful statistical advice.

The study was supported by research grants from the Swedish Research Council, the Council for Working Life and Social Research, and the Marianne and Marcus Wallenberg Foundation. None of the funding sources have influenced the study design, data collection, data analysis, manuscript preparation, or submission process.

References

1 Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM: Steroid hormone metabo-
lites are barbiturate-like modulators of the GABA receptor. Science 1986;232:1004–
1007.

2 Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salvestroni C, Tonetti A, et al. Circu-
lating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin
Endocrinol Metab 1998;83:2099–2103.

3 Ottander U, Poromaa IS, Bjurulf E, Skytt A, Andersson S, Jongejan MC, Postema EAM:
Allopregnanolone binding sites in the human corpus luteum. Mol Cell Endocrinol 2005;239:
37–44.

4 Dombroski RA, Casey ML, MacDonald PC: 5-Alpha-dihydroprogesterone formation in
human placenta from Salpha-pregnan-3beta/alpha-o1-20-ones and 5-pregnan-3beta-y1-
20-one sulfate. J Steroid Biochem Mol Biol 1997;63:155–163.

5 Luisi S, Petraglia F, Benedetto C, Nappi RE, Bernardi F, Sadati M, et al: Serum allopre-
gnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hyper-
tensive patients. J Clin Endocrinol Metab 2000;85:2429–2433.

6 Parizek A, Hill M, Kancheva R, Havlikova H, Kancheva I, Cindr J, et al: Neuroactive preg-
nanolone isomers during pregnancy. J Clin Endocrinol Metab 2005;90:395–403.

7 Nappi RE, Petraglia F, Luisi S, Polatti F, Fara 

8 Pearson Murphy BE, Steinberg SI, Hu FY, Al-

9 Timby E, Balgard M, Nyberg S, Spigset O, Andersson S, Porankiewicz-Aaslund J, et
al: Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl) 2006;186:414–
424.

10 Kask K, Bäckström T, Nilsson LG, Sundström-Poromaa J: Allopregnanolone im-
pairs episodic memory in healthy women. Psychopharmacology (Berl) 2008;199:161–
168.

11 Christensen H, Leach LS, Mackinnon A: Cog-
nition in pregnancy and motherhood: pro-
spective cohort study. Br J Psychiatry 2010;
196:126–132.

12 Romeo E, Strohle A, Spalletta G, di Michele F, Hermann B, Holbofer F, et al: Effects of anti-
depressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998;
155:910–913.
14 Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, et al: Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998;95:3239–3244.

15 Morgan ML, Rapkin AJ, Biggio G, Serra M, Zanwarzer P, Pasini A, et al: Plasma concentrations of neuroactive steroids before and after electroconvulsive therapy in major depression. Neuropsychopharmacology 2005;30:1181–1186.

16 Klatzkin RR, Morrow AL, Light KC, Pedersen CA, Girdler SS: Associations of histories of depression and PMDD with allopregnanolone. Psychoneuroendocrinology 2006;31:1208–1219.

17 Morgan ML, Rapkin AJ, Biggio G, Serra M, Pasini A, et al: Plasma concentrations of neuroactive steroids following the oral administration of micronized progesterone. Psychoneuroendocrinology 2006;31:1208–1219.

18 Gulinello M, Orman R, Smith SS: Sex differences in neuroactive steroids and gonadotropin-releasing hormone in pregnancy in the rat is induced by estrogen exposure in depressed postmenopausal women treated with sertraline and asymptomatic postmenopausal women. Arch Womens Ment Health 2010;13:91–98.

19 Galinello M, Orman R, Smith SS: Sex differences in anxiety, sensorimotor gating and expression of the alpha4b subunit of the GABA(A) receptor in the amygdala after progesterone withdrawal. Eur J Neurosci 2003;17:641–648.

20 Bitran D, Hilvers RJ, Kellogg CK: Anxiolytic effects of 3 alpha-hydroxy-5 alpha[beta]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res 1991;561:157–161.

21 Brunt PJ, McKay AJ, Ohdalski T, Piastowska A, Rebas E, Lachowicz A, et al: Central opioid inhibition of neuroendocrine stress responses in pregnancy in the rat is induced by the neurosteroid allopregnanolone. J Neurosci 2009;29:6449–6460.

22 de Souza EA, Teixeira-Silva F, Leite JR: The anxiolytic effect of pregnancy in rats is reversed by finasteride. Pharmacol Biochem Behav 2006;85:569–574.

23 Paoletti AM, Romagnino S, Contu R, Orru MM, Marotto MF, Zedda P, et al: Observational study on the stability of the psychological status during normal pregnancy and increased blood levels of neuroactive steroids with GABA-A receptor agonist activity. Psychoneuroendocrinology 2006;31:485–492.

24 Bickioka M, Tavola J, Hill M, Krausova Z, Hampfl R: Serum concentrations of some neuroactive steroids in women suffering from mixed anxiety-depressive disorder. Neurochem Res 2000;25:1623–1627.

25 Heydari B, Le Mellello JM: Low pregnenolone sulphate plasma concentrations in patients with generalized social phobia. Psychol Med 2002;32:929–933.